Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Truist Financial Analyst Says

Axsome Therapeutics (NASDAQ:AXSM) had its price target boosted by Truist Financial from $180.00 to $190.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price target would suggest a potential upside of 77.43% from the company’s current price.

A number of other analysts have also weighed in on the company. StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price objective on shares of Axsome Therapeutics in a report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and issued a $139.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, January 29th. HC Wainwright lifted their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $121.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.85.

Axsome Therapeutics Trading Up 0.6 %

Shares of Axsome Therapeutics stock traded up $0.63 on Monday, reaching $107.09. The company had a trading volume of 307,801 shares, compared to its average volume of 956,748. The firm has a market cap of $5.19 billion, a price-to-earnings ratio of -16.35 and a beta of 1.05. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The firm’s 50-day moving average price is $93.57 and its two-hundred day moving average price is $90.90. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $111.51.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The company had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same period in the previous year, the firm earned ($1.32) earnings per share. As a group, research analysts predict that Axsome Therapeutics will post -4.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Axsome Therapeutics

Institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Axsome Therapeutics in the 2nd quarter worth $27,000. R Squared Ltd acquired a new stake in Axsome Therapeutics in the fourth quarter worth about $64,000. KBC Group NV grew its stake in shares of Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after acquiring an additional 385 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares during the last quarter. Finally, Moors & Cabot Inc. purchased a new position in shares of Axsome Therapeutics in the 3rd quarter valued at approximately $200,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.